￥ 人民币 $ USD € 欧元
简体中文 English 繁体中文
Menu

Urology

Rucaparib (Rubraca): Full FDA-Approved Guide for BRCA-Mutated Prostate Cancer Treatment

2026-04-03 06:00:38

Rucaparib (brand name Rubraca) is a highly selective oral PARP inhibitor, granted full regular approval by the U.S. FDA on December 17, 2025, for the treatment of adult patients with deleterious BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC). This approval is based on pivotal data from the phase III TRITON3 trial, marking the conversion from accelerated approval to full approval, and providing a new precision targeted therapy option for patients with advanced prostate cancer.

Check Details
The latest prices for a box of different versions of Ukeron are announced

2025-10-19 11:44:20

Check Details
What is the price of genuine Ukeron in 2025?

2025-10-19 11:44:20

Check Details
Can Ukeron be purchased in China? Where can I buy it?

2025-10-19 11:44:20

Check Details
How much is the latest price of a box of Ukeron in 2025?

2025-10-19 11:44:20

Check Details
What are the purchasing channels for Ukeron?

2025-10-19 11:44:20

Check Details
The correct way to buy Ukeron

2025-10-19 11:44:20

Check Details
Oral Taibipenem HBr Receives Priority Review Qualification for Treatment of Complicated Urinary Tract Infections_ Kanghule

2025-10-19 11:44:20

Check Details
What is the latest price of a box of nitrohydroxyquinoline capsules in 2025?

2025-10-19 11:44:20

Check Details
Where can I purchase Nitroquinol Capsules?

2025-10-19 11:44:20

Check Details
How to alleviate the side effects of nitrohydroxyquinoline capsules

2025-10-19 11:44:20

Check Details
Usage and dosage of nitrohydroxyquinoline capsules

2025-10-19 11:44:20

Check Details
Category
相关知识